Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

NCT07332351 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07332351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
February 1, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder urothelial carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8